Improving asthma control among adult patients with asthma during increased outdoor pollution Respiratory
Conditions
Interventions
A mobile phone-based early alert system using high-resolution air quality forecast
Sponsors
Accord (United Kingdom)
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Adult patients aged 18 years old and above with physician-diagnosed asthma and receiving asthma treatment in the previous year 2. Adult patients who live in Klang District for the duration of the study 3. Patients who had reported poor asthma control and exacerbation aggravated by haze (findings from baseline study in RESPIRE 1) 4. Patients who are on controller medication (e.g., an inhaled corticosteroid (ICS), inhaled combination ICS/long-acting beta-agonists (LABA), leukotriene receptor antagonist (LTRA)) 5. Patients who own and are able to use a smartphone 6. Patients who are able to understand the Malay/English language 7. Patients who are willing and able to give consent to participate in the study
Exclusion criteria
Exclusion criteria: 1. Patients below 18 years of age 2. Patients who have respiratory symptoms (e.g., cough, breathlessness, wheezing) due to other conditions for example established physician diagnoses of: 2.1. Respiratory infection e.g., pneumonia, tuberculosis (but not having underlying asthma) 2.2. Chronic obstructive pulmonary diseases 2.3. Congenital heart disease 2.4. Heart, liver or renal failure 2.5. Gastro-esophageal reflux 2.6. Active life-threatening malignancy and those receiving palliative care 3. Patients who have disabilities (physical/psychological) that may interfere with the completion of the study 4. Patients who are unwilling or unable to provide written informed consent (e.g. cognitive impairment)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Asthma control measured using the Global Initiative for Asthma (GINA) Asthma Symptoms Control scoring at 1, 3, 6 and 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical endpoints assessed at baseline, 1, 3, 6 and 12 months: 1. Maximum speed of expiration measured using the peak expiratory flow rate (PEFR) value 2. Frequency of acute exacerbations (defined as episodes characterised by acute or subacute onset of progressively worsening symptoms, such as shortness of breath, cough, wheezing or chest tightness, which are worse than the patient's usual status and require a change in treatment) measured using patient questionnaire interviews and from patient medical record notes 3. Frequency of emergency visits due to asthma (emergency visit either to the health clinic and/or hospital emergency department) measured using patient questionnaire interviews and from patient medical record notes 4. Frequency of using an asthma action plan measured using patient questionnaire interviews 5. Frequency of using controller medications measured using patient questionnaire interviews and from patient medical record notes 6. Frequency of using reliever medications measured using patient questionnaire interviews and from patient medical record notes Frequency of using reliever medications: System endpoints assessed at 1, 3, 6 and 12 months: 1. Frequency of using the mobile health applications (app) (e.g., frequency of uploading daily symptoms and asthma diary) measured using data on users retrieved from the app 2. Frequency of reviewing the information (e.g., air pollution level) on the app measured using data on user retrieved from the app 3. System Usability Scale (ease of use, function integration, confidence in using) measured using the System Usability Scale questionnaire 4. Proportion of participant drop-out rates (not using the app) measured using patient questionnaire interviews and data on users retrieved from the app | — |
Countries
Malaysia
Outcome results
None listed